Log In / Register
SBEBCD for FDA-Approved Cannabinoid-based Medications
1 February, 2016
Virio Health, LLC announced that it has entered into exclusive license and supply agreement with Ligand Pharmaceuticals, Inc. for Captisol to be used for the development of cannabinoid-based medications.
The Captisol formulations are expected to avoid the usual side effects of opioids (death from overdose and debilitating addiction) for the treatment of chronic pain.
BACK TO NEWS